Literature DB >> 7909491

Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.

A S Lukes1, M F Kohler, C F Pieper, B J Kerns, R Bentley, G C Rodriguez, J T Soper, D L Clarke-Pearson, R C Bast, A Berchuck.   

Abstract

BACKGROUND: Several molecular-genetic alterations in endometrial cancers, including aneuploidy and aberrant expression of p53 and HER-2/neu, have been associated with poor prognosis. To determine the importance of molecular-genetic factors relative to more traditional surgical-pathologic prognostic factors, a multivariable analysis was performed.
METHODS: Immunohistochemical staining for p53, HER-2/neu, estrogen receptor, progesterone receptor, and epidermal growth factor receptor was performed on frozen sections from 100 primary endometrial cancers. DNA ploidy was determined using computerized image analysis of Feulgen-stained touch preparations. In addition, information regarding surgical-pathologic features of the cancers was obtained. Univariable analysis was performed followed by multivariable analysis using Cox's proportional hazards model to identify variables predictive of poor prognosis.
RESULTS: With univariable analysis, race, histologic type, stage, grade, myometrial invasion, estrogen receptor, progesterone receptor, ploidy, p53 and HER-2/neu were predictive of the presence of persistent or recurrent disease. In the multivariable analysis, only International Federation of Gynecology and Obstetrics stage (P = 0.005), grade (P = 0.005), myometrial invasion (P = 0.024), and ploidy (P = 0.028) were significant.
CONCLUSIONS: Among molecular-genetic prognostic factors, DNA ploidy was the most strongly predictive of persistent or recurrent disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909491     DOI: 10.1002/1097-0142(19940501)73:9<2380::aid-cncr2820730922>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial.

Authors:  Meenakshi Singh; Kathleen M Darcy; William E Brady; Rashna Clubwala; Zachary Weber; Jon V Rittenbach; Ali Akalin; Charles W Whitney; Richard Zaino; Nilsa C Ramirez; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2011-08-03       Impact factor: 5.482

2.  Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas.

Authors:  Simona Stolnicu; Iulia Barsan; Lien Hoang; Prusha Patel; Luis Chiriboga; Cristina Terinte; Anna Pesci; Sarit Aviel-Ronen; Takako Kiyokawa; Isabel Alvarado-Cabrero; Malcolm C Pike; Esther Oliva; Kay J Park; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2018-08       Impact factor: 6.394

3.  Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.

Authors:  Basil R Obeidat; Ismail I Matalka; Alia A Mohtaseb; Nabih S Al-Kaisi
Journal:  Pathol Oncol Res       Date:  2012-10-10       Impact factor: 3.201

Review 4.  Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study.

Authors:  J Rabczyński; P Ziółkowski
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

5.  Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis.

Authors:  L Riethdorf; C Begemann; S Riethdorf; K Milde-Langosch; T Löning
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

6.  Nuclear DNA analysis and prognosis in carcinoma of the thyroid gland. A nationwide study in Iceland on carcinomas diagnosed 1955-1990.

Authors:  J G Jónasson; J Hrafnkelsson
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 7.  Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.

Authors:  Sigurd F Lax
Journal:  Virchows Arch       Date:  2004-01-28       Impact factor: 4.064

Review 8.  The clinical significance of p53 aberrations in human tumours.

Authors:  S Bosari; G Viale
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 9.  Emerging therapeutic targets in endometrial cancer.

Authors:  Konstantin J Dedes; Daniel Wetterskog; Alan Ashworth; Stan B Kaye; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2011-01-11       Impact factor: 66.675

10.  Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion.

Authors:  John I Risinger; Jay Allard; Uma Chandran; Roger Day; Gadisetti V R Chandramouli; Caela Miller; Christopher Zahn; Julie Oliver; Tracy Litzi; Charlotte Marcus; Elizabeth Dubil; Kevin Byrd; Yovanni Cassablanca; Michael Becich; Andrew Berchuck; Kathleen M Darcy; Chad A Hamilton; Thomas P Conrads; G Larry Maxwell
Journal:  Front Oncol       Date:  2013-06-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.